Clinical Trial Update: Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating a combination of idarubicin, cytarabine, and vorinostat in high-risk myelodysplastic syndrome and acute myeloid leukemia; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Idarubicin (idarubicin)
• Vorinostat (vorinostat)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 2 | Status: COMPLETED | Results posted: 2015-03-09